NCT04743310 - Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

March 6, 2025

Study Completion Date

March 6, 2025

Conditions

Central Nervous System Tumor

Interventions

DRUG

tozuleristide

tozuleristide 24 or 36 mg administered intravenously 1-24 hours prior to surgery

DEVICE

Canvas imaging system

imaging device attached to surgical microscope

PROCEDURE

Surgical resection of tumor

Standard of care surgical resection of tumor

Trial Locations (1)

Cedars-Sinai Medical Center, Los Angeles